** is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
UBC9 is the sole E2 conjugating enzyme for SUMO (Small Ubiquitin-like Modifier) conjugation. It has a characteristic UBC9 fold consisting of a four-helix bundle structure that facilitates binding to SUMO and SUMOylated substrates. The active site contains a conserved cysteine residue (Cys93) that forms a thioester bond with SUMO during the conjugation process.
¶ Domain Architecture
- UBC9 Fold: Residues 1-158 - Catalytic core with SUMO-binding groove
- Active Site: Cys93 - Forms thioester intermediate with SUMO
- NLS/NES: Nuclear localization and export signals for shuttling
UBC9 plays critical roles in neuronal cells:
- SUMOylation: Catalyzes covalent attachment of SUMO to target proteins
- Transcriptional Regulation: Modifies transcription factors and co-regulators
- DNA Repair: Involved in genome stability through SUMOylation of repair proteins
- Synaptic Plasticity: Regulates synaptic protein function through SUMOylation
- Stress Response: Mediates cellular stress responses through SUMO-dependent pathways
UBC9 is essential for neuronal survival and function. It regulates numerous substrates involved in synaptic transmission, mitochondrial function, and protein quality control.
UBC9 and SUMOylation are implicated in AD pathogenesis:
- APP processing: SUMOylation affects amyloid precursor protein processing
- Tau pathology: SUMOylation of tau influences its aggregation and toxicity
- Synaptic dysfunction: Altered SUMOylation contributes to synaptic failure
In PD, UBC9:
- Alpha-synuclein: SUMOylation modulates α-synuclein aggregation and toxicity
- Mitochondrial function: Regulates mitochondrial proteins through SUMOylation
- Dopaminergic survival: Protects neurons from environmental toxins
UBC9 involvement in ALS:
- TDP-43 pathology: SUMOylation affects TDP-43 aggregation
- SOD1: SUMOylation of mutant SOD1 influences its toxicity
- RNA metabolism: Alters RNA-binding protein function
In HD, UBC9:
- Mutant huntingtin: SUMOylation modifies aggregation and toxicity
- Transcriptional dysregulation: Affects gene expression through transcription factor SUMOylation
- Mitochondrial dysfunction: Impairs energy metabolism
| Agent |
Mechanism |
Status |
Notes |
| SENP inhibitors |
Enhance SUMOylation by blocking deSUMOylation |
Research |
Increases neuroprotection |
| UBC9 modulators |
Enhance/decrease SUMOylation |
Preclinical |
Target-specific effects |
| SUMO analogs |
Mimic SUMOylation |
Research |
In development |
- SUMOylation levels in patient samples may reflect disease state
- UBC9 expression correlates with neurodegeneration markers
- Saitoh & Hinchey, Functional heterogeneity of SUMO (2000)
- Krumova et al., Sumoylation blocks alpha-synuclein aggregation (2011)
- Zhang et al., UBC9 deficiency leads to neurodegeneration (2013)
- Anderson et al., SUMOylation in synaptic plasticity (2015)